Drug2nd line
Mycophenolate mofetil
IMPDH inhibitor; suppresses lymphocyte proliferation
- Response rate
- Effective for maintenance after induction
- Onset
- Weeks–months
- Route
- Oral 1-3 g daily
- Line
- 2nd
- IgM effect
- Partial complement normalization
- Evidence level
- amber
Evidence summary
Effective maintenance therapy after cyclophosphamide induction. Worm et al. (2000) reported complete resolution of rash, arthralgias, arthritis, and uveitis. However, had no effect on obstructive lung disease. Less toxic than cyclophosphamide for long-term use.
Approved indications
Conditions for which Mycophenolate mofetil has regulatory approval (not specific to rare diseases covered here):
Organ Transplant RejectionLupus Nephritis
Drug identifiers
| DrugBank | DB00688 ↗ |
| ATC Code | L04AA06 |